{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["3(12)"],"submitter":["Terricabras M"],"pubmed_abstract":["<h4>Importance</h4>Catheter ablation is effective in reducing atrial fibrillation (AF), but the association of ablation for AF with quality of life is unclear.<h4>Objective</h4>To evaluate whether the procedural outcome of ablation for AF is associated with quality of life (QOL) measures.<h4>Design, setting, and participants</h4>This was a prespecified secondary analysis of the Substrate and Trigger Ablation for Reduction of Atrial Fibrillation-Part II (STAR AF II) prospective randomized clinical trial, which compared 3 strategies for ablation of persistent AF. This analysis included 549 of the 589 patients enrolled in the trial who underwent ablation. Enrollment occurred at 35 centers in Europe, Canada, Australia, China, and Korea from November 2010 to July 2012. Data for the current stud"],"journal":["JAMA network open"],"pagination":["e2025473"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC7718606"],"repository":["biostudies-literature"],"pubmed_title":["Association Between Quality of Life and Procedural Outcome After Catheter Ablation for Atrial Fibrillation: A Secondary Analysis of a Randomized Clinical Trial."],"pmcid":["PMC7718606"],"pubmed_authors":["Betts TR","Menardi E","Chen J","Sanders P","Deisenhofer I","Mantovan R","Morillo CA","Weerasooriya R","Verma A","Jiang CY","Albenque JP","Novak P","Terricabras M","Haverkamp W","Substrate and Trigger Ablation for Reduction of Atrial Fibrillation Trial–Part II (STAR AF II) Investigators","Nardi S","Macle L"],"additional_accession":[]},"is_claimable":false,"name":"Association Between Quality of Life and Procedural Outcome After Catheter Ablation for Atrial Fibrillation: A Secondary Analysis of a Randomized Clinical Trial.","description":"<h4>Importance</h4>Catheter ablation is effective in reducing atrial fibrillation (AF), but the association of ablation for AF with quality of life is unclear.<h4>Objective</h4>To evaluate whether the procedural outcome of ablation for AF is associated with quality of life (QOL) measures.<h4>Design, setting, and participants</h4>This was a prespecified secondary analysis of the Substrate and Trigger Ablation for Reduction of Atrial Fibrillation-Part II (STAR AF II) prospective randomized clinical trial, which compared 3 strategies for ablation of persistent AF. This analysis included 549 of the 589 patients enrolled in the trial who underwent ablation. Enrollment occurred at 35 centers in Europe, Canada, Australia, China, and Korea from November 2010 to July 2012. Data for the current stud","dates":{"release":"2020-01-01T00:00:00Z","publication":"2020 Dec","modification":"2026-04-18T01:12:57.467Z","creation":"2021-02-20T10:38:46Z"},"accession":"S-EPMC7718606","cross_references":{"pubmed":["33275151"],"doi":["10.1001/jamanetworkopen.2020.25473"]}}